ANDA 212218, held by Jubilant Cadista Pharmaceuticals. Clomipramine Hydrochloride.
As of Nov 21, 2026, ANDA 212218 (Clomipramine Hydrochloride), held by Jubilant Cadista Pharmaceuticals, was first approved by FDA on Oct 21, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 21, 2019 | Original application | Approved | None posted |
| Clomipramine Hydrochloride25MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride50MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride75MG · capsule;oral | Clomipramine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters